The Journal of Nutritional Biochemistry
Volume 18, Issue 8 , Pages 525-532 , August 2007

Glycitein activates extracellular signal-regulated kinase via vascular endothelial growth factor receptor signaling in nontumorigenic (RWPE-1) prostate epithelial cells

  • Elizabeth A. Clubbs
    • ,
  • Joshua A. Bomser

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Human Nutrition, The Ohio State University, Columbus, OH 43210, USA. Tel.: +1 614 247 6622; fax: +1 614 292 8880.

Received 1 June 2006 ,Revised 14 August 2006 ,Accepted 5 September 2006.

References 

  1. American Cancer Society. Cancer Facts and Figures, 2005. Available at: http://www.cancer.org.
  2. Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. Eur Urol. 1999;35:377–387
  3. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence an mortality. Int J Cancer. 2000;85:60–67
  4. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12:665–668
  5. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, et al. Vegetables, fruits, legumes, and prostate cancer: a multiethnic case–control study. Cancer Epidemiol Biomarkers Prev. 2000;9:795–804
  6. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Bio Chem. 1987;262:5592–5595
  7. Chen AC, Donovan SM. Genistein at a concentration present in soy infant formula inhibits Caco-2BBe cell proliferation by causing G2/M cell cycle arrest. J Nutr. 2004;134:1303–1308
  8. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2002;54:68–78
  9. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TTY, et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell cycle arrest in human prostate cancer cells. Mol Carcinog. 2002;29:92–102
  10. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer. 1998;32:123–131
  11. Wei H, Bowen R, Cai Q, Barnes S, Wang Y. Antioxidant and antipromotional effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med. 1995;208:124–130
  12. Wang J, Eltoum IE, Lamartiniere CA. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol. 2004;219:171–180
  13. Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, Wang H, et al. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer. 1999;35:130–136
  14. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr. 2002;132:552S–558S
  15. Wang X, Clubbs EA, Bomser JA. Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem. 2006;17:204–210
  16. Zava D, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer. 1997;27:31–40
  17. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998;58:3833–3838
  18. Allred CD, Ju YH, Allred KF, Chang J, Helferich WG. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcino. 2001;22:1667–1673
  19. Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF, et al. Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol. 2004;42:1641–1646
  20. Lund TD, Munson DJ, Haldy ME, Setchell KDR, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod. 2004;70:1188–1195
  21. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res. 2004;64:6190–6199
  22. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 2004;59:214–225
  23. Wang SH, Degroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-I-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nutr. 2003;133:2367–2376
  24. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, Jones K, et al. Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in Caucasian men. J Nutr. 2005;135:1400–1406
  25. Hedlund TE, Bokhoven A, Johannes WU, Nordeen SK, Ogden LG. Prostatic fluid concentrations of isoflavonoids in soy consumers are sufficient to inhibit growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2006;66:557–566
  26. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. Immunohistochemical demonstration of phosphor-Akt in high Gleason grade prostate cancer. Clin Cancer Res. 2002;8:1168–1171
  27. Leav I, Galluzzi CM, Ziar J, Stork PG, Ho SM, Loda M. Mitogen-activated protein kinase phosphatase-1 expression in the noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest. 1996;75:361–370
  28. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of p38MAPK, Erk1/2, and Jnk during the initiation and progression of prostate cancer. Prostate. 2003;55:128–139
  29. Ravi RK, McMahon M, Yangang Z, Williams JR, Dillehay LE, Nelkin BD, et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem. 1999;72:458–469
  30. Gioeli D, Mandell JW, Petroni GF, Frierson HF, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59:279–284
  31. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol. 1999;162:1537–1542
  32. Ise R, Han D, Takahashi Y, Terasaka S, Inoue A, Tanji M, et al. Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray. FEBS Lett. 2005;579:1732–1740
  33. Hagedorn A, Germann PG, Junker-Walker U, Tomovic A, Seewald W, Polkinghorne A, et al. Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. Exp Toxicol Pathol. 2005;57:149–159
  34. Wilgus TA, Matthies AM, Radek KA, Dovi JV, Burns AL, Shankar R, et al. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol. 2005;167:1257–1266
  35. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25
  36. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511–521
  37. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ. 2001;12:129–135
  38. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24:2647–2653
  39. Köllermann J, Helpap B. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. Am J Clin Pathol. 2001;116:115–121
  40. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol. 2000;164:506–510
  41. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urol. 1999;54:567–572
  42. Qi L, Robinson WA, Brady BMR, Glode LM. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Anticancer Res. 2003;23:3917–3922
  43. Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res. 2005;65(23):10921–10929
  44. Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am. 2004;18:951–971
  45. O'Neill E, Kolch W. Conferring specificity on the ubiquitous Raf/MEK signaling pathway. Br J Cancer. 2004;90:283–288

PII: S0955-2863(06)00231-2

doi: 10.1016/j.jnutbio.2006.09.005

The Journal of Nutritional Biochemistry
Volume 18, Issue 8 , Pages 525-532 , August 2007

Article Tools

* Image Usage & Resolution